Search

Your search keyword '"Polsky B"' showing total 207 results
Start Over Author "Polsky B"
207 results on '"Polsky B"'

6. Cytomegalovirus (CMV) and Human Immunodeficiency Virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360)

Author

Erice, A., Tierney, C., Hirsch, M., Caliendo, A.M, Weinberg, A., Kendall, M.A., and Polsky, B.

Subjects
HIV infection -- Care and treatment, HIV infection -- Genetic aspects, HIV infection -- Complications, Cytomegalovirus infections -- Care and treatment, Cytomegalovirus infections -- Genetic aspects, Cytomegalovirus infections -- Prognosis, Drug therapy, Combination -- Testing, Antiviral agents -- Testing, Health, Health care industry
Published
2003

10. Numerical simulation of submicrometer devices including coupled nonlocal transport and nonisothermal effects

Author

Apanovich, Y., Blakey, P., Cottle, R., Lyumkis, E., Polsky, B., Shur, A., and Tcherniaev, A.

Subjects
Charge transfer -- Observations, Miniature electronic equipment -- Research, Business, Electronics, Electronics and electrical industries
Abstract

A 2-D device simulator makes use of a self-consistent nonisothermal energy balance model applied to heterostructures. The simulator also studies changes in device characteristics due to coupling between nonlocal charge transport and nonisothermal effects. Comparison of results obtained using this model with previous results shows the drawbacks of previous models. Submicrometer silicon bipolar junction transistor and AlGaAs/GaAs HBT are studied.

Published
1995

13. Non-isothermal analysis of breakdown in SOI transistors

Author

Apanovich, Y., Lyumkis, E., Polsky, B., and Blakey, P.

Subjects
Silicon-on-isolator -- Research, Lattice dynamics -- Research, Temperature -- Research, Voltage -- Research, Semiconductors -- Research, Business, Electronics, Electronics and electrical industries
Abstract

The drain characteristics of a silicon-on-insulator transistor are determined by the simulation of non-isothermal devices. The breakdown voltage is lower than the lattice heating since the temperature coefficients of ionization are dependent on the temperature of ionization. This type of irregular behavior is caused by the temperature dependence of carrier injection by parasitic bipolar action. The breakdown behavior is dependent on the lattice temperature in the source region.

Published
1993

15. Computational analysis of mechanical and electromigration reliability problems

Author

Avci, I., primary, Balasingam, P., additional, Chawla, V., additional, El-Sayed, K., additional, Johnson, M. D., additional, Kucherov, A., additional, Li, S., additional, Mishra, B., additional, Oh, Y., additional, Polsky, B., additional, Qin, Z., additional, Simeonov, S., additional, Tian, S., additional, Xu, X., additional, Zhou, W., additional, and Zhu, M., additional

Published
2012
Full Text
View/download PDF

17. ChemInform Abstract: Synthesis and Anti-HIV Activity of 2′-“Up”-Fluoro Analogues of Active Anti-AIDS Nucleosides 3′-Azido-3′-deoxythymidine (AZT) and 2′,3′-Dideoxycytidine (DDC).

Author

WATANABE, K. A., primary, HARADA, K., additional, ZEIDLER, J., additional, MATULIC-ADAMIC, J., additional, TAKAHASHI, K., additional, REN, W. Y., additional, CHENG, L.-C., additional, FOX, J. J., additional, CHOU, T.-C., additional, ZHU, Q. Y., additional, POLSKY, B., additional, GOLD, J. W. M., additional, and ARMSTRONG, D., additional

Published
2010
Full Text
View/download PDF

18. ChemInform Abstract: Nucleosides. Part 158. Fluorinated Sugar Analogues of Potential Anti- HIV-1 Nucleosides.

Author

HUANG, J.-T., primary, CHEN, L.-C., additional, WANG, L., additional, KIM, M.-H., additional, WARSHAW, J. A., additional, ARMSTRONG, D., additional, ZHU, Q.-Y., additional, CHOU, T.-C., additional, WATANABE, K. A., additional, MATULIC-ADAMIC, J., additional, SU, T.-L., additional, FOX, J. J., additional, POLSKY, B., additional, BARON, P. A., additional, GOLD, J. W. M., additional, HARDY, W. D., additional, and ZUCKERMAN, E., additional

Published
2010
Full Text
View/download PDF

23. Three-dimensional TCAD Process and Device Simulations

Author

Avci, I., primary, Balasingam, P., additional, El Sayed, K., additional, Gharib, J., additional, Johnson, M.D., additional, Kells, K., additional, Kiralyfalvi, G., additional, Koltyzhenkov, V., additional, Kucherov, A., additional, Lyumkis, E., additional, Penzin, O., additional, Polsky, B., additional, Rao, V., additional, Simeonov, S.D., additional, Strecker, N., additional, Tan, Z., additional, Villablanca, L., additional, and Fichtner, W., additional

Published
2006
Full Text
View/download PDF

32. Randomized Phase I Trial of Two Different Combination Foscarnet and Ganciclovir Chronic Maintenance Therapy Regimens for AIDS Patients with Cytomegalovirus Retinitis: AIDS Clinical Trials Group Protocol 151

Author

Jacobson, M A, primary, Kramer, F, additional, Bassiakos, Y, additional, Hooton, T, additional, Polsky, B, additional, Geheb, H, additional, O’Donnell, J J, additional, Walker, J D, additional, Korvick, J A, additional, and van der Horst, C, additional

Published
1995
Full Text
View/download PDF

33. Relationship Between Plasma Concentrations Of 3'-Deoxy-3'-Fluorothymidine (Alovudine) And Antiretroviral Activity In Two Concentration-Controlled Trials

Author

Flexner, C., primary, van der Horst, C., additional, Jacobson, M. A., additional, Powderly, W., additional, Duncanson, F., additional, Ganes, D., additional, Barditch-Crovo, P. A., additional, Petty, B. G., additional, Baron, P. A., additional, Armstrong, D., additional, Bricmont, P., additional, Kuye, O., additional, Yacobi, A., additional, Desjardins, R., additional, and Polsky, B., additional

Published
1994
Full Text
View/download PDF

35. Randomized Phase I Trial of Two Different Combination Foscarnet and Ganciclovir Chronic Maintenance Therapy Regimens for AIDS Patients with Cytomegalovirus Retinitis: AIDS Clinical Trials Group Protocol 151

Author

Jacobson, M. A., primary, Kramer, F., additional, Bassiakos, Y., additional, Hooton, T., additional, Polsky, B., additional, Geheb, H., additional, O'Donnell, J. J., additional, Walker, J. D., additional, Korvick, J. A., additional, and van der Horst, C., additional

Published
1994
Full Text
View/download PDF

44. A cluster of four cases of Mycobacterium haemophilum infection.

Author

Kiehn, T., White, M., Pursell, K., Boone, N., Tsivitis, M., Brown, A., Polsky, B., and Armstrong, D.

Abstract

Four cases of infection with Mycobacterium haemophilum occurred at a single hospital in a seven-month period. Only 22 cases have been reported since 1976. All four patients were immunocompromised; two had AIDS and two were the first known recipients of allogeneic bone marrow transplants (BMT) to develop the infection. One BMT recipient died of Mycobacterium haemophilum pneumonia. The organism requires hemin or ferric ammonium citrate and incubation of media at 30 °C for optimum growth. Clinicians and microbiologists should consider infection with Mycobacterium haemophilum, particularly when specimens are from immuno-compromised patients with unexplained illness and/or when acid-fast bacilli are seen on smear. [ABSTRACT FROM AUTHOR]

Published
1993
Full Text
View/download PDF

45. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome.

Author

Polsky, Bruce, Gold, Jonathan W.M., Whimbey, Estella, Dryjanski, Jose, Brown, Arthur E., Schiffman, Gerald, Armstrong, Donald, Polsky, B, Gold, J W, Whimbey, E, Dryjanski, J, Brown, A E, Schiffman, G, and Armstrong, D

Subjects
PNEUMONIA, AIDS patients
Abstract

Eighteen episodes of community-acquired bacterial pneumonia were diagnosed in 13 patients among 336 with the acquired immunodeficiency syndrome (AIDS) cared for at Memorial Sloan-Kettering Cancer Center since 1979. Bacterial pathogens isolated in 16 of 18 episodes were Haemophilus influenzae in 8, Streptococcus pneumoniae in 6, group B streptococcus in 1, and Branhamella catarrhalis in 1. Eight episodes were presumed Pneumocystis carinii pneumonia until cultures obtained at bronchoscopy confirmed a bacterial cause. Specific antibacterial therapy was curative in 16 of 18 episodes; 2 patients died. Given an estimated yearly incidence of pneumococcal pneumonia in the general population of 2.6/1000, 1.09 cases were expected in our patients with AIDS; we saw 6 (p = 0.001), for an attack rate of 17.9/1000. Bacteria associated with B-cell defects should be anticipated when formulating empiric antibiotic therapy, pending a definitive diagnosis, for pulmonary infiltrates in patients with AIDS. [ABSTRACT FROM AUTHOR]

Published
1986
Full Text
View/download PDF

46. Herpes encephalitis in monoclonal gammopathy.

Author

Graber JJ, Rus H, Zivin-Tutela T, and Polsky B

Abstract

Fever, behavioral changes, and new-onset seizures in a 73-year-old man with a history monoclonal gammopathy of unknown significance (MGUS) was traced to a herpes simplex virus infection. Although herpes encephalitis has not yet been reported in a patient with MGUS, it has been reported in persons with multiple myeloma and plasmacytoma. Immune system abnormalities associated with oncological conditions and MGUS may result in failure to suppress latent herpes virus infection. [ABSTRACT FROM AUTHOR]

Published
2009

47. Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine, an in vivo metabolite of oltipraz.

Author

Prochaska, H J, Bornmann, W G, Baron, P, and Polsky, B

Abstract

Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication in vitro (ED50 approximately 10 microM), undergoes extensive metabolism in vivo. Most of the orally administered drug undergoes opening of the dithiolethione ring, reduction, recyclization, and methylation to form 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine ("metabolite III"). We report here that metabolite III inhibits viral replication in vitro (ED50 approximately 25 microM) in acutely infected H9 and CEM T cell lymphoma cell lines. Although both metabolite III and oltipraz were able to inhibit phorbol-12-myristate-13-acetate-stimulated viral replication in the chronically infected U1 promonocytic leukemia cell line, only metabolite III was able to inhibit phorbol-12-myristate-13-acetate-stimulated viral replication in chronically infected ACH-2 T cell lymphoma cells. The results with ACH-2 cells suggest that oltipraz inhibits an early stage of the viral life cycle, whereas metabolite III affects human immunodeficiency virus type 1 replication at a step distal to viral integration. This is consistent with the finding that oltipraz inhibits reverse transcriptase, whereas metabolite III does not. Although the mean ED50 for metabolite III in acutely infected peripheral blood mononuclear cells was 18 microM, the ED50 was below 5 microM in three of eight independent experiments. Studies of metabolite III in combination with oltipraz in acutely infected peripheral blood mononuclear cells demonstrated significant antiviral synergy. These results raise the possibility that the in vitro potency of oltipraz may underestimate its antiretroviral activity in vivo. Based on these results, the pharmacokinetics of oltipraz and metabolite III will be compared with the pharmacodynamic effects of orally administered oltipraz in a forthcoming phase I/II trial of oltipraz in patients with p24 antigenemia.

Published
1995

49. Elevation of glutathione levels by phase II enzyme inducers: lack of inhibition of human immunodeficiency virus type 1 replication in chronically infected monocytoid cells.

Author

Prochaska, H J, Rubinson, L, Yeh, Y, Baron, P, and Polsky, B

Abstract

Supplementation of media with high concentrations of thiols (5-20 mM) inhibits human immunodeficiency virus type 1 (HIV-1) replication in vitro. Compounds that prevent carcinogenesis via induction of phase II enzymes also elevate intracellular GSH levels, thus raising the possibility that chemopreventive enzyme inducers may represent a more pharmacologically feasible method to inhibit viral replication. Previous studies revealed that oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione] was the only GSH inducer tested that could inhibit HIV-1 replication in acutely infected H9 cells. Because thiols are proposed to suppress transcription of the integrated HIV-1 genome by preventing the activation of nuclear factor-kappa B, experiments evaluating inducers of GSH levels in acutely infected H9 cells do not rule out the ability of these compounds to inhibit viral replication in chronically infected cells exposed to cytokines or mitogens. Therefore, we determined the antiviral effects of several inducers in phorbol-12-myristate-13- acetate-stimulated U1 cells, a monocytoid cell line that contains two integrated copies of the HIV-1 genome. Although 1,2-dithiole-3-thione, dimethyl fumarate, and oltipraz can elevate cytosolic thiol levels, only oltipraz inhibited HIV-1 replication. Moreover, decreased nuclear factor-kappa B binding activity could be correlated with increases in cytosolic thiols produced by various treatments (r2 = 0.8) but not with suppression of viral replication (r2 = 0.01). These data suggest that oltipraz-induced increases in GSH are not responsible for the antiviral action of oltipraz and that elevation of intracellular GSH levels by chemopreventive enzyme inducers does not inhibit viral replication.

Published
1994

50. Successful Treatment of Old World Cutaneous Leishmaniasis Caused by Leishmania infantumwith Posaconazole

Author

Paniz Mondolfi, A. E., Stavropoulos, C., Gelanew, T., Loucas, E., Perez Alvarez, A. M., Benaim, G., Polsky, B., Schoenian, G., and Sordillo, E. M.

Abstract

ABSTRACTOld World cutaneous leishmaniasis is a widespread and potentially disfiguring protozoal infection that is endemic in the Mediterranean basin, Africa, and parts of Asia. Human infection is caused by several species of Leishmaniaparasites, such as Leishmania infantum. Available systemic and topical treatments vary in efficacy and are often unjustified due to their toxicity. We report on a case that was treated with posaconazole, a drug typically considered an antifungal agent but which also targets specific metabolic pathways of the parasite.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results